Drug Company Set to Pay $15 Million to DOJ Over Doctor Bribery Scandal
Burn it down. Burn it all down. "Mallinckrodt Pharmaceuticals announced today that the company expects to pay $15.4 million in a settlement with the U.S. Justice Department after allegations that Questcor Pharmaceuticals, which Mallinckrodt acquired in 2014, had bribed doctors and their staff to prescribe an incredibly expensive drug. Two whistleblowers came forward in April to accuse Questcor of trying to boost profits for Acthar, a medication primarily for infants with seizures. Questcor raised the price of the medication by almost 100,000 percent (not a typo) from just $40 in 2000 to $38,892 today, despite the fact that Acthar has been on the market since 1952. Mallinckrodt currently rakes in about $1 billion per year from Acthar, according to CNN. ... Curiously, there’s a drug called Synacthen that’s identical to Acthar and sells for just $33 in Canada. So why isn’t Synacthen available in the U.S.? Because Mallinckrodt bought the U.S. rights to Synacthen and simply doesn’t make it available to American consumers."
No comments:
Post a Comment